Seres Therapeutics (MCRB) Return on Capital Employed (2015 - 2026)
Seres Therapeutics (MCRB) posted Return on Capital Employed of 80.73% for Q1 2026, down 4.39% sequentially from 77.34% in Q4 2025, and up 1383.0% YoY from 5.44% in Q1 2025.
Seres Therapeutics (MCRB) Return on Capital Employed (2015 - 2026) Analysis & Trends
Seres Therapeutics has reported Return on Capital Employed for 12 years, with the latest figure at 80.73% in Q1 2026.
- Quarterly Return on Capital Employed rose 1383.0% year-over-year to 80.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 80.73% (up 1383.0% YoY) and the FY2025 annual result came in at 78.52%, down 2019.0% from the prior year.
- Return on Capital Employed fell to 80.73% in Q1 2026 per MCRB's latest filing, from 77.34% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 21.88% in Q3 2023 and troughed at 108.02% in Q3 2022.
- A 5-year average of 66.23% and a median of 73.52% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed tumbled 9420 bps in 2022, then surged 8614 bps in 2023.
- Over 5 years, Return on Capital Employed stood at 73.52% in 2022, then surged by 47 bps to 38.81% in 2023, then tumbled by 165 bps to 102.76% in 2024, then gained by 25 bps to 77.34% in 2025, then dropped by 4 bps to 80.73% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 80.73%, 77.34%, and 85.33% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | -93.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -93.82% |
| Mar 31, 2026 | -80.73% |
| Dec 31, 2025 | -77.34% |
| Sep 30, 2025 | -85.33% |
| Jun 30, 2025 | -89.49% |
| Mar 31, 2025 | -94.56% |
| Dec 31, 2024 | -102.76% |
| Sep 30, 2024 | -69.85% |
| Jun 30, 2024 | -64.92% |
| Mar 31, 2024 | -26.46% |
| Dec 31, 2023 | -38.81% |
| Sep 30, 2023 | -21.88% |
| Jun 30, 2023 | -31.45% |
| Mar 31, 2023 | -79.26% |
| Dec 31, 2022 | -73.52% |
| Sep 30, 2022 | -108.02% |
| Jun 30, 2022 | -48.24% |
| Mar 31, 2022 | -33.30% |
| Dec 31, 2021 | -21.99% |
| Sep 30, 2021 | -13.83% |